PUBLISHER: IMARC | PRODUCT CODE: 1468402
PUBLISHER: IMARC | PRODUCT CODE: 1468402
The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.
In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.
The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, GLP type and indication.
Rodent
Rats
Mice
Others
Non-Rodent
Non-GLP
In House
Outsourcing
GLP Toxicology
In House
Outsourcing
Autoimmune/Inflammation Conditions
Rheumatoid Arthritis
Multiple Sclerosis
Osteoarthritis
Irritable Bowel Syndrome
Others
Pain Management
Chronic Pain
Acute Pain
Oncology
Blood Cancer
Solid Tumor
Others
CNS Conditions
Epilepsy
Parkinson's Disease
Huntington's Disease
Stroke
Traumatic Brain Injury
ALS
Muscle Regeneration
Others
Diabetes
Obesity
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.